CD274 and breast cancer: Recent clinical trial studies exploiting immune-checkpoint blockade with monoclonal antibodies against PD-1 and PD-L1 for metastatic BC have shown highly encouraging results, although only one-fifth of the patients who overexpress PD-1 and/or PD-L1 will likely benefit4, 9.